The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma.
Various prognostic factors were studied in 29 patients with stage III or IV ovarian cancer who responded to initial chemotherapy after initial diagnostic surgery. The half-life of CA 125 in serum during initial chemotherapy was the most important prognostic indicator for survival (P less than 0.001) and the chance of achieving complete remission (P = 0.012). A CA 125 half-life of less than 20 days, 20-40 days and greater than 40 days appears to identify patients with a good, intermediate or poor prognosis, the two year actuarial survival being 76%, 48% and 0% respectively. The change of achieving a complete remission was 15% and 67% respectively for patients with a serum CA 125 half-life of greater than 20 or less than 20 days.
Hawkins
R E
RE
Department of Medicine, Royal Marsden Hospital, London.
Roberts
K
K
Wiltshaw
E
E
Mundy
J
J
Fryatt
I J
IJ
McCready
V R
VR
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D005260:Female; D006207:Half-Life; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate
D015295:Antigens, Tumor-Associated, Carbohydrate